Chemomab Therapeutics Ltd. Quarterly Debt-to-equity in % from Q3 2020 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Chemomab Therapeutics Ltd. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q2 2023.
  • Chemomab Therapeutics Ltd. Debt-to-equity for the quarter ending June 30, 2023 was 20.2 %, a 264% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 20.2 +14.6 +264% Jun 30, 2023
Q1 2023 15 +10.6 +243% Mar 31, 2023
Q4 2022 10.9 +6 +123% Dec 31, 2022
Q3 2022 7.78 +2.25 +40.7% Sep 30, 2022
Q2 2022 5.54 -2.29 -29.2% Jun 30, 2022
Q1 2022 4.37 -7.55 -63.4% Mar 31, 2022
Q4 2021 4.9 -15.5 -76% Dec 31, 2021
Q3 2021 5.53 -20.8 -79% Sep 30, 2021
Q2 2021 7.83 Jun 30, 2021
Q1 2021 11.9 Mar 31, 2021
Q4 2020 20.4 Dec 31, 2020
Q3 2020 26.4 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.